Use of extractive of bcg polysaccharide and nucleic acid for preparing medicine for treating viral skin diseases, and its injection and preparation method

Use of extractive of bcg polysaccharide and nucleic acid for preparing medicine for treating viral skin diseases, and its injection and preparation method

  • CN 101,686,993 A
  • Filed: 01/07/2008
  • Published: 03/31/2010
  • Est. Priority Date: 01/07/2008
  • Status: Active Application
First Claim
Patent Images

1. Claimsa kind of application of BCG polysaccharide nucleic acid extractive in the medicine for preparing treatment virus dermatopathy, wherein the BCG polysaccharide nucleic acid extractive contains the moisture that polysaccharide, nucleic acid, the BCG vaccine mycoprotein of residual and weight/mass percentage composition are less than 10%, wherein polysaccharide weight/mass percentage composition is 70-78%, Nucleic acid quality percentage composition is 12-20%, the BCG vaccine mycoprotein quality percentage composition of residual is 0-0.5%, the residual quantity of phenol is zero, and miscellaneous bacteria number is 0-20/grams.application of the BCG polysaccharide nucleic acid extractive in the medicine for preparing treatment virus dermatopathy according to claim 1, it is characterised in that the BCG polysaccharide nucleic acid extractive is prepared by following steps:

  • (a) is cultivated BCG vaccine, and harvests BCG vaccine culture;

    (b) is crushed using physical method to above-mentioned BCG vaccine culture, obtains BCG polysaccharide nucleic acid suspension;

    (c) is handled above-mentioned BCG polysaccharide nucleic acid suspension using 30-100 °

    C of phenol combination supercentrifugal process is added, and obtains BCG polysaccharide nucleic acid mixture;

    (d) is separated by gel filtration chromatography method to above-mentioned BCG polysaccharide nucleic acid mixture, obtains BCG polysaccharide nucleic acid extract solution, the further isolated BCG polysaccharide nucleic acid extractive from the BCG polysaccharide nucleic acid extract solution.3. application of the BCG polysaccharide nucleic acid extractive in the medicine for preparing treatment virus dermatopathy according to claim 1, it is characterised in that described virus dermatopathy and the immunologic function of patient are unbalance relevant.4. application of the BCG polysaccharide nucleic acid extractive in the medicine for preparing treatment virus dermatopathy according to claim 1, it is characterised in that described virus dermatopathy is infected relevant with body.5. application of the BCG polysaccharide nucleic acid extractive in the medicine for preparing treatment virus dermatopathy according to claim 3 or 4, it is characterised in that described virus dermatopathy is caused by HPV.6. application of the BCG polysaccharide nucleic acid extractive according to claim 5 in the medicine for preparing treatment virus dermatopathy, it is characterised in that described virus dermatopathy includes flat wart and condyloma acuminatum etc..7. application of the BCG polysaccharide nucleic acid extractive in the medicine for preparing treatment virus dermatopathy according to claim 1, it is characterised in that the medicine of described treatment virus dermatopathy includes BCG polysaccharide nucleic acid injection.8. application of the BCG polysaccharide nucleic acid extractive according to claim 7 in the medicine for preparing treatment virus dermatopathy, it is characterized in that described BCG polysaccharide nucleic acid injection contains polysaccharide, nucleic acid, the BCG vaccine mycoprotein and pharmaceutically acceptable auxiliary material of residual, wherein polyoses content is 0.32 mg/ml 0.38mg/ml, nucleic acid content is the 5 ((^g/ml of ^g/ml 10, BCG vaccine mycoprotein content is the g/ml of 0 g/ml 2.5, and the residual quantity and miscellaneous bacteria number of phenol are zero.9. application of the BCG polysaccharide nucleic acid extractive according to claim 8 in the medicine for preparing treatment virus dermatopathy, it is characterized in that the pharmaceutically acceptable auxiliary material in the BCG polysaccharide nucleic acid injection includes sodium chloride, wherein sodium chloride content is 9mg/ml.10. a kind of BCG polysaccharide nucleic acid injection for being used to treat virus dermatopathy, contain BCG-polysaccharide, nucleic acid, the BCG vaccine mycoprotein and pharmaceutically acceptable auxiliary material of residual, it is characterised in that wherein polyoses content is that 0.32mg/ml 0.38mg/ml, nucleic acid content are the 5 (μ

    of ^g/ml 100§

    / η

    ι

    BCG vaccine mycoproteins content is 0 μ

    §

    1 2.5 μ

    of/η

    ι



    ι

    1, the residual quantity of phenol is zero.11. the BCG polysaccharide nucleic acid injection according to claim 10 for being used to treat virus dermatopathy, it is characterised in that miscellaneous bacteria number therein is zero.12. being used for according to claim 11 treats the BCG polysaccharide nucleic acid injection of virus dermatopathy, it is characterised in that the pharmaceutically acceptable auxiliary material includes sodium chloride, and wherein sodium chloride content is 9mg/ml.13. a kind of prepare the method as claimed in claim 10 for being used to treat the BCG polysaccharide nucleic acid injection of virus dermatopathy, it is characterised in that comprise the following steps-(a) cultivates BCG vaccine, and harvests BCG vaccine culture;

    (b) crushes the BCG vaccine culture using physical method, obtains BCG polysaccharide nucleic acid suspensionLiquid;

    (c) handles the BCG polysaccharide nucleic acid suspension using 30-100 °

    C of phenol combination supercentrifugal process is added, and obtains BCG polysaccharide nucleic acid mixture;

    (d) separates the BCG polysaccharide nucleic acid mixture by gel filtration chromatography method, BCG polysaccharide nucleic acid extract solution is obtained, and alcohol precipitation is carried out to the BCG-polysaccharide extract solution, sediment is collected, dried after sediment washing, dried object is BCG polysaccharide nucleic acid extractive;

    (e) BCG polysaccharide nucleic acid extractive is diluted in the water for injection containing pharmaceutically acceptable auxiliary material by, it is mixed to hook, it is 0.32 mg/ml 0.38mg/ml to make the polyoses content in final solution, nucleic acid content is the 5 (g/ml of ^g/ml 100, BCG vaccine mycoprotein content is the g/ml of 0 g/ml 2.5, moist heat sterilization is dispensed after the solution is filtered, and produces BCG polysaccharide nucleic acid injection.14. the preparation according to claim 13 is used for the method for treating the BCG polysaccharide nucleic acid injection of virus dermatopathy, it is characterised in that step(

    E) the pharmaceutically acceptable auxiliary material described in includes sodium chloride, and wherein content of the sodium chloride in gained BCG polysaccharide nucleic acid injection is 9mg/ml.15. the preparation according to claim 13 is used for the method for treating the BCG polysaccharide nucleic acid injection of virus dermatopathy, it is characterised in that step(

    E) pH value is adjusted to 6.0 7.2 with pH value regulator before being additionally included in filtering.16. the preparation according to claim 15 is used for the method for treating the BCG polysaccharide nucleic acid injection of virus dermatopathy, it is characterised in that the pH value regulator includes sodium hydroxide and hydrochloric acid.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×